T-cell Acute Lymphoblastic Leukemia Clinical Trial
— BAH246Official title:
This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL).
Verified date | May 2024 |
Source | Essen Biotech |
Contact | JAMAL ALKHAYER |
Phone | +97333799773 |
ceo[@]essen-biotech.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be the potential to develop the corresponding CAR-T cells to treat patients whose tumors express those markers. In this study, investigators will evaluate the safety and efficacy of Sequential CAR-T Cells Targeting CD5/CD7 in patients with patients with relapsed or refractory T-ALL/LBL/ETP-ALL. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 28, 2026 |
Est. primary completion date | December 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 90 Years |
Eligibility | Inclusion Criteria: - Signed written informed consent; Patients volunteer to participate in the clinical trial; - Diagnosis is mainly based on the World Health Organization (WHO) 2008; - Complete remission cannot be achieved after induction therapy; recurrence occurs after completion remission; the burden of leukemic blasts in the peripheral blood or bone marrow is greater than 5%; - Leukemic blast cells express CD7/CD5 (CD7 OR CD5 positive by flow cytometry or immunohistochemistry =70%); - The expected survival period is greater than 12 weeks; - ECOG score =2; - Age 2-60 years old; - HGB=70g/L (can be transfused); - Total bilirubin does not exceed 3 times the upper limit of normal value, and AST and ALT do not exceed 5 times the upper limit of normal value. Exclusion Criteria: - Patients declining to consent for treatment - Prior solid organ transplantation - One of the following cardiac issues: atrial fibrillation; myocardial infarction within the past 12 months; prolonged QT syndrome or secondary QT prolongation; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV; - History of severe pulmonary dysfunction diseases; - Severe infection or persistent infection cannot be effectively controlled; - Severe autoimmune disease or congenital immunodeficiency; - Active hepatitis; - Human immunodeficiency virus (HIV) infection; - Clinically significant viral infections, or uncontrollable viral reactivation, including EBV (Epstein-Barr virus). |
Country | Name | City | State |
---|---|---|---|
China | District one hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Essen Biotech |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number and incidence of adverse events after CD7/CD5 CAR infusion. | Evaluation of all possible adverse reactions, including the number, incidence, and severity of symptoms such as cytokine release syndromes and neurotoxicity within 3 months after CAR-T infusion | 28 days | |
Primary | Disease response to CD7/CD5 CAR T cells | The disease response to CD7/CD5 CAR T cells is evaluated by bone marrow biopsy and aspirate within 1 year after CAR infusion. The proportion of subjects receiving CD7/CD5 CAR T infusion to 1) morphological remission (blasts <5%): 2) flow cytometry analysis was blast negative, and 3) molecular biological remission (if applicable). | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05032599 -
Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT04033302 -
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05995028 -
Universal 4SCAR7U Targeting CD7-positive Malignancies
|
Phase 1 | |
Recruiting |
NCT05596266 -
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Completed |
NCT01950286 -
Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.
|
N/A | |
Completed |
NCT02518113 -
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03081910 -
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
|
Phase 1 | |
Recruiting |
NCT05290155 -
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05289687 -
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
|
Phase 2 | |
Recruiting |
NCT04972942 -
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
|
Phase 1 | |
Recruiting |
NCT06316427 -
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05277753 -
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
|
Phase 1 | |
Not yet recruiting |
NCT06390319 -
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
|
Phase 2 | |
Recruiting |
NCT05679895 -
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
|
Phase 1 | |
Active, not recruiting |
NCT04984356 -
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
|
Phase 1/Phase 2 | |
Recruiting |
NCT05832125 -
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
|
||
Withdrawn |
NCT04860817 -
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
|
Early Phase 1 | |
Recruiting |
NCT04594135 -
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04934774 -
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
|
Phase 1 | |
Enrolling by invitation |
NCT05509855 -
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
|